Sanofi Sees Dupixent As Just The Start Of COPD Transformation
Itepekimab Also In Development
Executive Summary
Dupixent’s surprise success in COPD is welcome news, but it remains uncertain whether regulators will demand a second study readout before filing. In the meantime, Sanofi highlighted another promising late-stage candidate for the hard-to-treat disease during its Q1 results.
You may also be interested in...
After IPO Success, Apogee Prepares To Take On Lilly And Sanofi Dupixent Across I&I
Using a 'de-risked business model' of targeting established drug categories with next-generation antibodies, Apogee is looking to take on Lilly’s lebrikizumab and Sanofi’s Dupixent.
Dupixent Succeeds Where Other Biologic Drugs Failed – In COPD
Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.
Sanofi Goes All In For Type 1 Diabetes With Provention Buy
Sanofi is taking full control of the recently approved type 1 diabetes prevention therapy Tzield by splashing out $2.9bn to acquire partner Provention.